anti-BCMA CAR-NK (LNP-mRNA)

Anti-BCMA CAR-NK (LNP-mRNA) is an experimental, preclinical cell therapy approach in which natural killer (NK) cells are engineered to transiently express a chimeric antigen receptor (CAR) targeting B-cell maturation antigen (BCMA) via lipid nanoparticle (LNP)-mediated mRNA delivery. The active ingredient consists of mRNA encoding an anti-BCMA CAR construct (typically incorporating an anti-BCMA scFv linked to intracellular signaling domains such as 4-1BB and CD3ζ), encapsulated in lipid nanoparticles and delivered into NK cells (either NK-92 cell lines or primary human NK cells). The biological target is BCMA (B-cell maturation antigen, encoded by TNFRSF17), a cell surface receptor preferentially expressed on mature B lymphocytes and malignant plasma cells. The primary disease indication is relapsed/refractory multiple myeloma. The modality is a cell-based gene therapy / biologic (CAR-NK cell therapy using non-viral mRNA-LNP delivery). Unlike viral vector-based CAR-T therapies, this approach enables transient CAR expression, reducing risks of insertional mutagenesis and immunogenicity, and supports 'off-the-shelf' allogeneic use.

Other names

anti-BCMA CAR-NK cells (mRNA-LNP)BCMA-targeted mRNA-LNP CAR-NK cells